Denise C Connolly

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. pmc Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
  2. ncbi request reprint Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
  3. pmc Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice
    Harvey H Hensley
    Biological Imaging Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Neoplasia 14:451-62. 2012
  4. ncbi request reprint Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
  5. ncbi request reprint Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  6. ncbi request reprint Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
  7. ncbi request reprint RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
  8. doi request reprint Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents
    Denise C Connolly
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Curr Protoc Pharmacol . 2009
  9. pmc Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009
  10. pmc Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 14:994-1004. 2012

Collaborators

Detail Information

Publications11

  1. pmc Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
    ..The objective of this study was to establish an immunocompetent syngeneic mouse model of disseminated epithelial ovarian cancer (EOC) to facilitate laboratory-based studies of ovarian tumor biology and preclinical therapeutic strategies...
  2. ncbi request reprint Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
    ..Our results demonstrate that MRI is well tolerated and can be repeated in serial imaging studies, permitting quantitative analysis of tumor growth and progression and response to therapeutic interventions...
  3. pmc Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice
    Harvey H Hensley
    Biological Imaging Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Neoplasia 14:451-62. 2012
    ....
  4. ncbi request reprint Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
    ....
  5. ncbi request reprint Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  6. ncbi request reprint Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
    ..To investigate whether the survivin promoter controls cancer cell-specific gene expression, we determined whether the survivin gene promoter could regulate reporter gene expression in cancer cell lines and xenografts...
  7. ncbi request reprint RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
    ....
  8. doi request reprint Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents
    Denise C Connolly
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Curr Protoc Pharmacol . 2009
    ....
  9. pmc Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009
    ..In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome...
  10. pmc Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 14:994-1004. 2012
    ..Finally, the mouse VEGF(164) transcript was underexpressed in C3(KO) livers compare to C3(WT) livers. Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression...
  11. pmc NEDD9 promotes oncogenic signaling in mammary tumor development
    Eugene Izumchenko
    Program in Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Res 69:7198-206. 2009
    ..This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness...